Key result
ACE2/Ang 1-7/Mas axis offers counter-regulatory therapeutic potential across cardiovascular and pulmonary diseases.
Highlights the therapeutic potential of targeting the ACE2/Ang-(1-7)/Mas axis for cardiovascular and pulmonary diseases.
Does not support immediate clinical use; leaves open efficacy of ACE2/Ang-(1-7)/Mas-targeted therapies in cardiovascular and pulmonary diseases.
Angiotensin (Ang)-(1-7) is now recognized as a biologically active component of the renin-angiotensin system (RAS). The discovery of the angiotensin-converting enzyme homologue ACE2 revealed important metabolic pathways involved in the Ang-(1-7) synthesis. This enzyme can form Ang-(1-7) from Ang II or less efficiently through hydrolysis of Ang I to Ang-(1-9) with subsequent Ang-(1-7) formation. Additionally, it is well established that the G protein-coupled receptor Mas is a functional ligand site for Ang-(1-7). The axis formed by ACE2/Ang-(1-7)/Mas represents an endogenous counter regulatory pathway within the RAS whose actions are opposite to the vasoconstrictor/proliferative arm of the RAS constituted by ACE/Ang II/AT(1) receptor. In this review we will discuss recent findings concerning the biological role of the ACE2/Ang-(1-7)/Mas arm in the cardiovascular and pulmonary system. Also, we will highlight the initiatives to develop potential therapeutic strategies based on this axis.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2012) conducted a review in Cardiovascular and pulmonary diseases. ACE2/Ang-(1-7)/Mas Receptor Axis modulation was evaluated. The ACE2/Ang-(1-7)/Mas axis represents an endogenous counter-regulatory pathway within the renin-angiotensin system with potential as a therapeutic target for cardiovascular and pulmonary diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: